Optimized and safe use of topical corticosteroids in pediatric dermatology through interdisciplinary collaboration: a review

Abstract

AbstractThe use of topical corticosteroids (TCs) in pediatric patients is a common therapeutic approach for various dermatological conditions. However, their application can lead to a spectrum of adverse drug reactions (ADRs), from localized skin changes to systemic effects. Due to factors such as thinner skin, enhanced cutaneous absorption, and developing organ systems, pediatric populations are particularly vulnerable to TCs-led ADRs. The most common ADRs associated with the use of TCs in the pediatric population include skin atrophy, striae, and telangiectasia. Other less common ADRs include allergic contact dermatitis, perioral dermatitis, and systemic effects such as suppression of the hypothalamic–pituitary–adrenal (HPA) axis, etc. To minimize the possibility of ADRs and unwanted medication reactions, rational and safe use of TCs shall be promoted. Clinical Pharmacists (CPs) play a pivotal role in ensuring appropriate and safe utilization of TCs in pediatric patient care. CPs collaborate with healthcare practitioners to design individualized treatment regimens considering factors such as age, skin type, and medical history. They also educate patients and caregivers on proper TCs application techniques, therapy duration, and potential side effects, thereby facilitating better adherence and treatment outcomes. Clinical research specific to pediatric populations is essential to provide precise insights into TCs effectiveness and safety, accounting for age-related variations and long-term consequences. TCs represent a valuable tool in pediatric dermatology, but their use requires careful consideration of the risks and benefits, active involvement of CPs, regulatory measures, and ongoing research to optimize therapy outcomes and safety in pediatric patients.